Anti-TIMP1/ CLGI/ EPA functional antibody
Anti-TIMP1/ CLGI/ EPA functional antibody for cell culture, ELISA & in-vivo assay
Go to TIMP1/TIMP1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0506-Ab-1/ GM-Tg-hg-SE0506-Ab-2 | Anti-Human TIMP1 monoclonal antibody | Human |
GM-Tg-rg-SE0506-Ab-1/ GM-Tg-rg-SE0506-Ab-2 | Anti-Rat TIMP1 monoclonal antibody | Rat |
GM-Tg-mg-SE0506-Ab-1/ GM-Tg-mg-SE0506-Ab-2 | Anti-Mouse TIMP1 monoclonal antibody | Mouse |
GM-Tg-cynog-SE0506-Ab-1/ GM-Tg-cynog-SE0506-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TIMP1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0506-Ab-1/ GM-Tg-felg-SE0506-Ab-2 | Anti-Feline TIMP1 monoclonal antibody | Feline |
GM-Tg-cang-SE0506-Ab-1/ GM-Tg-cang-SE0506-Ab-2 | Anti-Canine TIMP1 monoclonal antibody | Canine |
GM-Tg-bovg-SE0506-Ab-1/ GM-Tg-bovg-SE0506-Ab-2 | Anti-Bovine TIMP1 monoclonal antibody | Bovine |
GM-Tg-equg-SE0506-Ab-1/ GM-Tg-equg-SE0506-Ab-2 | Anti-Equine TIMP1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0506-Ab-1/ GM-Tg-hg-SE0506-Ab-2; GM-Tg-rg-SE0506-Ab-1/ GM-Tg-rg-SE0506-Ab-2; GM-Tg-mg-SE0506-Ab-1/ GM-Tg-mg-SE0506-Ab-2; GM-Tg-cynog-SE0506-Ab-1/ GM-Tg-cynog-SE0506-Ab-2; GM-Tg-felg-SE0506-Ab-1/ GM-Tg-felg-SE0506-Ab-2; GM-Tg-cang-SE0506-Ab-1/ GM-Tg-cang-SE0506-Ab-2; GM-Tg-bovg-SE0506-Ab-1/ GM-Tg-bovg-SE0506-Ab-2; GM-Tg-equg-SE0506-Ab-1/ GM-Tg-equg-SE0506-Ab-2 |
Products Name | Anti-TIMP1 monoclonal antibody |
Format | mab |
Target Name | TIMP1 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Diagnostic target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-TIMP1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0506-Ag-1 | Recombinant multi-species TIMP1/ CLGI/ EPA protein |
ORF Viral Vector | vGMAP000469 | Human TIMP1 Adenovirus particle |
ORF Viral Vector | pGMAP000553 | Human TIMP1 Adenovirus plasmid |
ORF Viral Vector | pGMAP000455 | Human TIMP1 Adenovirus plasmid |
ORF Viral Vector | vGMAP000455 | Human TIMP1 Adenovirus particle |
ORF Viral Vector | vGMAP000553 | Human TIMP1 Adenovirus particle |
ORF Viral Vector | pGMLV000257 | human TIMP1 Lentivirus plasmid |
ORF Viral Vector | pGMAP000469 | Human TIMP1 Adenovirus plasmid |
ORF Viral Vector | vGMLV000257 | human TIMP1 Lentivirus particle |
ORF Viral Vector | pGMLP001347 | human NM_003254humanNM_003254 Lentivirus plasmid |
ORF Viral Vector | vGMLP001347 | human NM_003254humanNM_003254 Lentivirus particle |
ORF Viral Vector | pGMLPm000328 | mouse Timp1 Lentivirus plasmid |
ORF Viral Vector | vGMLPm000328 | mouse Timp1 Lentivirus particle |
Target information
Target ID | GM-SE0506 |
Target Name | TIMP1 |
Gene ID | 7076,21857,116510,574348,403816,101095886,282092,100034220 |
Gene Symbol and Synonyms | CLGI,EPA,EPO,HCI,TIMP,TIMP-1,TIMP1,TPA-S1 |
Uniprot Accession | P01033,P30120,Q95KL9,P81546,P20414,O02722 |
Uniprot Entry Name | TIMP1_HUMAN,TIMP1_MACMU,TIMP1_RAT,TIMP1_CANLF,TIMP1_BOVIN,TIMP1_HORSE |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Diagnostics Biomarker |
Disease | Dent disease, Vesicoureteral reflux |
Gene Ensembl | ENSG00000102265 |
Target Classification | N/A |
The target: TIMP1, gene name: TIMP1, also named as CLGI, EPA, EPO, HCI, TIMP, TIMP-1. This gene belongs to the TIMP gene family. The proteins encoded by this gene family are natural inhibitors of the matrix metalloproteinases (MMPs), a group of peptidases involved in degradation of the extracellular matrix. In addition to its inhibitory role against most of the known MMPs, the encoded protein is able to promote cell proliferation in a wide range of cell types, and may also have an anti-apoptotic function. Transcription of this gene is highly inducible in response to many cytokines and hormones. In addition, the expression from some but not all inactive X chromosomes suggests that this gene inactivation is polymorphic in human females. This gene is located within intron 6 of the synapsin I gene and is transcribed in the opposite direction. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.